1034188-33-4

Basic information

• Product Name: isopropyl 4-isopropoxy-3-(trifluoromethyl)benzoate
• Synonyms: isopropyl 4-isopropoxy-3-(trifluoromethyl)benzoate
• CAS NO: 1034188-33-4
• Molecular Weight: 290.282
• Mol File: 1034188-33-4.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: isopropyl 4-isopropoxy-3-(trifluoromethyl)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: isopropyl 4-isopropoxy-3-(trifluoromethyl)benzoate(1034188-33-4)
• EPA Substance Registry System: isopropyl 4-isopropoxy-3-(trifluoromethyl)benzoate(1034188-33-4)

Safety Data

• Hazardous Substances Data: 1034188-33-4(Hazardous Substances Data)

Upstream product

• 220239-68-9 4-hydroxy-3-(trifluoromethyl)benzoic acid 
• 75-26-3 isopropyl bromide 
• 75-30-9 2-iodo-propane 

Downstream Products

• 213598-16-4 4-isopropoxy-3-(trifluoromethyl)benzoic acid 
• 1215119-43-9 (R)-2-(9-chloro-7-((4-isopropoxy-3-(trifluoromethyl)benzyl)oxy)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl)acetic acid 
• 1333379-92-2 (R)-ethyl 2-(9-chloro-7-((4-isopropoxy-3-(trifluoromethyl)benzyl)oxy)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl)acetate 
• 1333379-91-1 (R)-ethyl 2-(7-((4-isopropoxy-3-(trifluoromethyl)benzyl)oxy)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl)acetate 
• 1215119-52-0 (S)-2-(2-(4-isopropoxy-3-(trifluoromethyl)benzyloxy)-6,7,8,9-tetrahydropyrido[1,2-a]indol-9-yl)acetic acid 
• 1215119-51-9 (R)-2-(2-(4-isopropoxy-3-(trifluoromethyl)benzyloxy)-6,7,8,9-tetrahydropyrido[1,2-a]indol-9-yl)acetic acid 
• 1215119-10-0 Ethyl 2-(2-(4-isopropoxy-3-(trifluoromethyl)benzyloxy)-6,7,8,9-tetrahydropyrido[1,2-a]indol-9-yl)acetate 
• 1215118-59-4 2-(2-(4-isopropoxy-3-(trifluoromethyl)benzyloxy)-6,7,8,9-tetrahydropyrido[1,2-a]indol-9-yl)acetic acid 
• 1215118-98-1 tert-butyl 2-(7-(4-isopropoxy-3-(trifluoromethyl)benzyloxy)-9-methyl-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl)acetate 
• 1215118-97-0 tert-butyl 2-(9-iodo-7-(4-isopropoxy-3-(trifluoromethyl)benzyloxy)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl)acetate 
• 1215118-50-5 2-(7-(4-isopropoxy-3-(trifluoromethyl)benzyloxy)-9-methyl-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl)acetic acid 
• 1215118-95-8 tert-butyl 2-(7-(4-isopropoxy-3-(trifluoromethyl)benzyloxy)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl)acetate 
• 1215118-94-7 4-(chloromethyl)-1-isopropoxy-2-(trifluoromethyl)benzene 
• 1215118-92-5 (4-isopropoxy-3-(trifluoromethyl)phenyl)methanol 

Relevant articles and documents

COMPOUNDS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS

The present invention relates to certain compounds of Formula (Ia) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor: Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of S1P1 receptor-associated disorders, for example, a disease or disorder mediated by lymphocytes, an autoimmune disease or disorder, an inflammatory disease or disorder, an inflammatory skin disease or disorder, cancer, psoriasis, atopic dermatitis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, and acne, microbial infections or diseases and viral infections or diseases.

(7-Benzyloxy-2,3-dihydro- 1H -pyrrolo[1,2-a]indol-1-yl)acetic acids as S1P1 functional antagonists

S1P1 is a validated target for treatment of autoimmune disease, and functional antagonists with superior safety and pharmacokinetic properties are being sought as second generation therapeutics. We describe the discovery and optimization of (7-benzyloxy-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl)acetic acids as potent, centrally available, direct acting S1P1 functional antagonists, with favorable pharmacokinetic and safety properties.

TRICYCLIC HETEROCYCLIC COMPOUNDS

Disclosed are compounds of Formula (I) or stereoisomers or salts thereof, wherein: X1, X2, X3, W, Q1, Q2, and G2 are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.